Overview of the global needle-free drug delivery market
According to needle-free drug delivery market outlook, the global needle-free drug delivery market will grow at a CAGR of more than 10% during the forecast period. One of the key drivers that will stimulate the growth of the market in the coming years is the rising demand for the self-administration of drugs. A large number of patients are preferring self-administration of drugs using needle-free delivery devices to reduce healthcare costs. The introduction of self-injectable medications in rheumatoid arthritis encouraged patients to adopt self-administered medications. The influx of patients adopting self-administered medications for this disease increased from 53% to 70% during 2012. This fueled the demand for needle-free drug delivery products among these consumers because they eliminate the risk of needle-stick injuries and cross-contamination. The adoption of the self-administration of drugs using needle-free delivery systems reduces healthcare expenses as it enables patients to receive treatment in non-medical settings. This encourages pharmaceutical companies to come up with new self-administration drugs that can be delivered through needleless injections or devices.
The US is the major revenue contributor towards the needle-free drug delivery market in the Americas. Developed countries such as the US and Canada focus on the development, commercialization, and adoption of needle-free drug delivery devices. Several players operating in the US are investing in research and developmental activities to test new drug applications. The application of these drugs involves needle-free drug delivery devices such as jet injectors, transdermal patches, and other novel needle-free drug technologies.
Competitive landscape and key vendors
The needle-free drug delivery market comprises a large number of vendors. To introduce new products and enhance existing products to attain more innovative, advanced, and user-friendly product, companies are heavily investing in research and developmental activities. Many companies are heavily investing in the development of microneedle drug delivery systems to gain more market shares. The introduction of new technologies and devices will strengthen the market’s competitive environment.
Key vendors in this market are
- Endo Pharmaceuticals
- Antares Pharma
- Inovio Pharmaceuticals
- Valeritas
- PharmaJet
Other prominent vendors in the market include 3M, Akra Dermojet, Consort Medical, CROSSJECT, Injex Pharma, PenJet Corporation, Zosano, D’Antonio Consultants International, and European Pharma Group.
Segmentation by product or technology and analysis of the needle-free drug delivery market
- Jet injectors
- Transdermal drug delivery systems
One of the needle-free injection systems, the jet injector uses a high-pressure narrow stream of fluid to penetrate the skin instead of a hypodermic needle. The jet injector segment accounted for the majority market share during 2016 because it involves zero contamination. Individuals are increasingly adopting self-administration of drugs to reduce healthcare expenses. Also, a patient with needle phobia prefers pain-free injections. The rising incidence of needle stick injuries and the increasing prevalence of diabetes and infectious diseases will drive the segment’s growth during the estimated period.
Segmentation by application and analysis of the needle-free drug delivery market
- Insulin delivery
- Vaccination
- Pain management
The application of needle-free drug delivery systems for insulin delivery accounted for the maximum shares during 2016 due to a rapid increase in the prevalence of diabetes in both the developed and developing countries. Nearly 20% of people diagnosed with diabetes in North America depend on the daily administration of insulin. Also, approximately 50% of diabetic patients using insulin in Europe are opting for needle-free jet injectors. The consumer preference for needle-free insulin delivery will increase over conventional needle injections for the next four years since they eliminate the pain associated with needle insulin delivery.
Key questions answered in the report include
- What will the market size and the growth rate be in 2021?
- What are the key factors driving the global needle-free drug delivery market?
- What are the key market trends impacting the growth of the global needle-free drug delivery market?
- What are the challenges to market growth?
- Who are the key vendors in the global needle-free drug delivery market?
- What are the market opportunities and threats faced by the vendors in the global needle-free drug delivery market?
- What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
- What are the key outcomes of the five forces analysis of the global needle-free drug delivery market?
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 06: Market segmentation by product/technology
- Jet injectors
- Market size and forecast
- Transdermal drug delivery systems
- Market size and forecast
- Others
- Market size and forecast
PART 07: Market segmentation by application
- Market segmentation by application
- Insulin delivery
- Vaccination
- Pain management
- Others
PART 08: Geographical segmentation
- Market overview
- Americas
- EMEA
- APAC
PART 09: Decision framework
PART 10: Drivers and challenges
- Market drivers
- Market challenges
PART 11: Market trends
- Technological innovations
- Increasing outsourcing
- M&A and strategic collaborations
PART 12: Vendor landscape
PART 13: Key vendor analysis
- Endo Pharmaceuticals
- Antares Pharma
- Inovio Pharmaceuticals
- Valeritas
- PharmaJet
- Other prominent vendors
PART 14: Appendix